Clinical trial
Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave…
NCT00489840 · Manhattan Eye, Ear & Throat Hospital, Other · Completed
Key facts
| NCT number | NCT00489840 |
|---|---|
| Title | Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate |
| Official title | Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate |
| Acronym | CSC-AA |
| Lead sponsor | Manhattan Eye, Ear & Throat Hospital, Other |
| Collaborators | LuEsther T. Mertz Retinal Research Center Alcon Research Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Central Serous Chorioretinopathy |
| Intervention type | Drug |
| Interventions | Anecortave Acetate Sterile suspension 15 mg, Anecortave Acetate |
| Enrollment | 5 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2010 |
| First posted | Jun 21, 2007 |
| Last update posted | Oct 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: